The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study.
Wendy Onstenk
No relevant relationships to disclose
Jaco Kraan
No relevant relationships to disclose
Ayoub Charehbili
No relevant relationships to disclose
Bianca Mostert
No relevant relationships to disclose
Vincent T. H. B. M. Smit
No relevant relationships to disclose
Judith R. Kroep
Research Funding - Amgen; Novartis; Sanofi
J. W. R. Nortier
No relevant relationships to disclose
Gerrit-Jan Liefers
No relevant relationships to disclose
Saskia van de Ven
No relevant relationships to disclose
Joan Barbara Heijns
No relevant relationships to disclose
Lonneke Kessels
No relevant relationships to disclose
Hanneke W. M. Van Laarhoven
No relevant relationships to disclose
Monique M.E.M. Bos
No relevant relationships to disclose
Cornelis J. H. Van De Velde
No relevant relationships to disclose
Jan-Willem Gratama
No relevant relationships to disclose
Anieta M. Sieuwerts
No relevant relationships to disclose
John W. M. Martens
No relevant relationships to disclose
John A. Foekens
Research Funding - Veridex
Stefan Sleijfer
Research Funding - Veridex